Next Article in Journal
Implementation of Electronic Consent at a Biobank: An Opportunity for Precision Medicine Research
Previous Article in Journal
Barriers and Facilitators to Adoption of Genomic Services for Colorectal Care within the Veterans Health Administration
Article Menu

Export Article

Open AccessArticle
J. Pers. Med. 2016, 6(2), 15; doi:10.3390/jpm6020015

Personalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard

Faculty of Law and Economics, Department of Health Care Management, Ernst-Moritz-Arndt-University, Greifswald 17489, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen B. Liggett
Received: 29 December 2015 / Revised: 19 April 2016 / Accepted: 21 April 2016 / Published: 2 May 2016
View Full-Text   |   Download PDF [1178 KB, uploaded 2 May 2016]   |  

Abstract

The aim of our research was to collect comprehensive data about the public and physician awareness, acceptance and use of Personalized Medicine (PM), as well as their opinions on PM reimbursement and genetic privacy protection in the U.S. and Germany. In order to give a better overview, we compared our survey results with the results from other studies and discussed Personalized Medicine preconditions for its wide implementation into the medical standard. For the data collection, using the same methodology, we performed several surveys in Pennsylvania (U.S.) and Bavaria (Germany). Physicians were contacted via letter, while public representatives in person. Survey results, analyzed by means of descriptive and non-parametric statistic methods, have shown that awareness, acceptance, use and opinions on PM aspects in Pennsylvania and Bavaria were not significantly different. In both states there were strong concerns about genetic privacy protection and no support of one genetic database. The costs for Personalized Medicine were expected to be covered by health insurances and governmental funds. Summarizing, we came to the conclusion that for PM wide implementation there will be need to adjust the healthcare reimbursement system, as well as adopt new laws which protect against genetic misuse and simultaneously enable voluntary data provision. View Full-Text
Keywords: personalized medicine; personalized drug; pharmacogenetic test personalized medicine; personalized drug; pharmacogenetic test
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kichko, K.; Marschall, P.; Flessa, S. Personalized Medicine in the U.S. and Germany: Awareness, Acceptance, Use and Preconditions for the Wide Implementation into the Medical Standard. J. Pers. Med. 2016, 6, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top